- Piramal Pharma Solutions (PPS) has received a $1,753,620 investment from the Ontario government through the Life Sciences Scale-Up Fund to upgrade infrastructure at its Aurora, Canada drug substance site.
- PPS is investing $5.314 million in the project, which will support R&D and clinical API production, commercial availability of drug substances, and 12 new jobs while protecting 183 existing positions.
Piramal Pharma Solutions (PPS), a global contract development and manufacturing organization (CDMO) and part of Piramal Pharma Ltd., has received $1,753,620 from the Ontario government through the Life Sciences Scale-Up Fund. The funding will support infrastructure upgrades at PPS’s Aurora, Canada drug substance site and the commercialization of Ontario-made health technologies for new markets.
With the government support, PPS is investing $5.314 million to upgrade infrastructure at the Aurora facility. The project will strengthen pharmaceutical manufacturing and domestic API production in Ontario, while enhancing R&D and clinical API production and supporting the commercial availability of critical drug substances.
The investment is expected to create 12 new jobs and protect 183 existing positions. PPS said the site upgrades will also support projects focused on sustainability, operational efficiency, and site modernization.
The Ontario government launched the $24 million Life Sciences Scale-Up Fund in 2024 to support the development, commercialization, and deployment of health technologies. The 2026 Ontario Budget provided an additional $24 million to the fund, according to the release.
“We are grateful to the Government of Ontario and MPP Dawn Gallagher Murphy for their support of this important investment in our Aurora facility. This funding will help enable Piramal Pharma Solutions to upgrade our site infrastructure, strengthen our manufacturing capabilities, and enhance our ability to serve patients and customers around the world.”
Peter DeYoung, CEO, Piramal Global Pharma
